Back to top

Analyst Blog

Mallinckrodt (MNK - Snapshot Report) recently presented positive data on its pain candidate, MNK-795, from a multicenter, randomized, double-blind, placebo-controlled, parallel-arm, multiple-dose phase III study.

Mallinckrodt said that a statistically significant improvement in pain scores was achieved by MNK-795 compared to placebo from baseline over 48 hours. The study was conducted in patients with acute pain following a unilateral first metatarsal bunionectomy.

This study is a part of the 505 (b)(2) application submitted by Mallinckrodt to the FDA for MNK-795. The 505 (b)(2) regulatory pathway allows a company to depend partly on data from existing reference drugs.

MNK-795, an extended-release oral formulation of oxycodone and acetaminophen, is currently under FDA review. The candidate has been studied for the management of moderate to severe acute pain where the use of an opioid analgesic is suitable.

The phase III data was presented in the first week of September at PAINWeek, a national conference on pain for frontline practitioners.

Mallinckrodt also presented data from a human abuse liability (HAL) study which was conducted to compare certain abuse-related characteristics of MNK-795 with those of Percocet, an immediate-release formulation of oxycodone/acetaminophen.

Results showed that measures of drug liking, drug high and good drug effects in intact and crushed MNK-795 were lower compared to Percocet when measured at the peak drug effect. The results were statistically significant.

With the FDA granting priority review status to MNK-795, a final response regarding its approval should be out later this year.

Mallinckrodt currently carries a Zacks Rank #4 (Sell). At present, companies like Supernus Pharmaceuticals, Inc. (SUPN - Snapshot Report), Actelion Ltd. (ALIOF) and Actavis, Inc. (ACT - Analyst Report) look well-positioned. While Supernus and Actelion are Zacks Rank #1 (Strong Buy) stocks, Actavis is a Zacks Rank #2 (Buy) stock.
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GREEN PLAIN… GPRE 36.46 +3.79%
MATRIX SERV… MTRX 30.90 +2.93%
ENZO BIOCHE… ENZ 5.20 +2.77%
GENTIVA HEA… GTIV 15.82 +2.73%
VIPSHOP HOL… VIPS 191.34 +2.23%